Current Opinion in Oncology最新文献_第4页

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-01-01 Epub Date: 2024-12-05 DOI: 10.1097/CCO.0000000000001109

引用次数: 0

Perioperative immunotherapy in nonsmall cell lung cancer. 非小细胞肺癌围手术期免疫疗法。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-01-01 Epub Date: 2024-09-05 DOI: 10.1097/CCO.0000000000001098

Renzhi Zhang, Chun Zou, Liang Zeng, Yongchang Zhang

{"title":"Perioperative immunotherapy in nonsmall cell lung cancer.","authors":"Renzhi Zhang, Chun Zou, Liang Zeng, Yongchang Zhang","doi":"10.1097/CCO.0000000000001098","DOIUrl":"10.1097/CCO.0000000000001098","url":null,"abstract":"Purpose of review: To evaluate and summarize the current clinical efficacy, safety, treatment patterns, and potential biomarkers, to guide future treatment strategies for nonsmall cell lung cancer (NSCLC), improve patient prognosis, and provide a scientific basis for personalized therapy.Recent findings: In recent years, the class of immune checkpoint inhibitors (ICIs), with programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors at the helm, has catalyzed groundbreaking advancements within the perioperative treatment milieu for NSCLC. With the positive results of several phase III clinical trials, perioperative immunotherapy has been confirmed to significantly reduce the risk of postoperative recurrence in resectable NSCLC, becoming the new standard for perioperative treatment of stages II to III NSCLC. With the advent of the perioperative immunotherapy era, clinical issues such as the selection of the treatment population, the choice of regimen, the duration of treatment, whether patients with pCR need further adjuvant therapy, and the comprehensive management of patients throughout the perioperative period have attracted widespread attention.Summary: The perioperative treatment of NSCLC has fully entered the era of immunotherapy. Multiple clinical studies have confirmed that perioperative immunotherapy can significantly improve the survival benefit of resectable stages II to III NSCLC, establishing a new standard for the perioperative treatment of stages II to III NSCLC.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"40-47"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perioperative immunotherapy for nonsmall cell lung cancer. 非小细胞肺癌围手术期免疫疗法。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-01-01 Epub Date: 2024-09-25 DOI: 10.1097/CCO.0000000000001100

Jingya Huang, Wenyuan Li, Hui Guo

{"title":"Perioperative immunotherapy for nonsmall cell lung cancer.","authors":"Jingya Huang, Wenyuan Li, Hui Guo","doi":"10.1097/CCO.0000000000001100","DOIUrl":"10.1097/CCO.0000000000001100","url":null,"abstract":"Purpose of review: Recent years have witnessed significant advancements in the treatment of lung cancer with immunotherapy, primarily centered on immune checkpoint inhibitors (ICIs). Numerous clinical studies have evaluated or are currently evaluating the clinical benefits of neoadjuvant, adjuvant, and perioperative use of ICIs. These findings have notably reshaped the landscape of perioperative treatment for nonsmall cell lung carcinoma (NSCLC).Recent findings: Comparing different treatment modes, adding ICIs in the adjuvant phase to neoadjuvant treatment with ICIs and chemotherapy may not improve survival outcomes for patients with resectable NSCLC and may be associated with increased adverse events. For prognostic factors, ctDNA minimal residual disease (MRD) status might serve as an early predictor of achieving pathological remission. For study endpoints, a positive result with PFS as the primary endpoint may not necessarily translate into overall survival benefits.Summary: For perioperative immunotherapy, challenges persist, including the current lack of sensitive and reliable biomarkers, the effect of neoadjuvant therapy on surgical risk as well as the selection of the appropriate study endpoint. In this review, we discuss recent and ongoing trials investigating strategies of neoadjuvant, adjuvant and perioperative immunotherapy in NSCLC, while also proposing considerations for future directions in this continuously evolving field.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"63-72"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel vaccines against lung cancer. 新型肺癌疫苗

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-01-01 Epub Date: 2024-10-01 DOI: 10.1097/CCO.0000000000001102

Sofia Baka, George Iraklis, Evanthia Papadopoulou

{"title":"Novel vaccines against lung cancer.","authors":"Sofia Baka, George Iraklis, Evanthia Papadopoulou","doi":"10.1097/CCO.0000000000001102","DOIUrl":"10.1097/CCO.0000000000001102","url":null,"abstract":"Purpose of review: Despite recent advances in immunotherapy treatment for metastatic, early-stage nonsmall cell lung cancer (NSCLC), palliative, adjuvant, neoadjuvant, and perioperative treatment options, further development is needed. Exploring new frontiers of immuno-oncology is necessary. Researchers are interested in a therapeutic vaccination model.Recent findings: In this paper, we provide a review of the latest lung cancer therapeutic vaccines.We describe strategies for antigen selection and delivery platforms. As of 5 th of August 2024, we have reviewed ongoing clinical trials and results.We summarize most of the important clinical trials of novel vaccines, the way of action, and available clinical data. We also discuss the pros and cons of various types of therapeutic vaccines.Summary: Until recently, clinical trial results were mixed regarding the efficacy of therapeutic vaccines in lung cancer.Developing next-generation sequencing and bioinformatic technologies has helped identify suitable antigens. New personalized vaccines are based on neoantigens specific to unique tumor mutations.Neoantigens, instead of tumor-associated antigens, better delivery systems and adjuvants will improve antigen presentation and immune system activation.Combining these therapeutic vaccines with other therapeutic approaches will improve and prolong the response.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"73-83"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reproductive life and differentiated thyroid carcinoma in women: reciprocal influences on their respective outcome. 妇女的生育期和分化型甲状腺癌：对各自结果的相互影响。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-01-01 Epub Date: 2024-10-11 DOI: 10.1097/CCO.0000000000001104

Giuseppe Costante, Aglaia Kyrilli, Kris Poppe

{"title":"Reproductive life and differentiated thyroid carcinoma in women: reciprocal influences on their respective outcome.","authors":"Giuseppe Costante, Aglaia Kyrilli, Kris Poppe","doi":"10.1097/CCO.0000000000001104","DOIUrl":"10.1097/CCO.0000000000001104","url":null,"abstract":"Purpose of review: To analyze the reciprocal influences between female reproductive life and DTC management.Recent findings: Data on pregnancy outcome in DTC patients indicate that after conceiving, these women may need an increased L-T4 dose to maintain suppressed serum TSH levels. Nevertheless, this does not determine major harm in terms of pregnancy outcome. Analogously, the most recent findings obtained with the propensity score matching approach have confirmed that pregnancy does not significantly affect DTC clinical course and eventually tumor prognosis. A recent metanalysis and a large case-control study excluded a significant effect of radioactive iodine treatment (RAIT) on several reproductive variables in DTC patients, providing reassuring evidence that the current recommendations on RAIT for women of childbearing age are sufficiently well tolerated and do not affect fertility nor pregnancy rate. Nonetheless, it seems reasonable to recommend special attention for older than 35 years women requiring higher RAIT activities.Summary: Overall, the most recent studies have provided sufficiently reassuring evidence that the occurrence of pregnancy and DTC management are of no reciprocal harm for adverse outcome in affected women of childbearing age. Thus, female DTC patients should be managed according to the individual response to treatment before pregnancy. When DTC diagnosis is made after conception, delaying surgery does not represent a harm in most patients.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"7-11"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Action against thoracic cancers: recent achievements and perspectives. 对抗胸部癌症的行动：最近的成就和展望。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-01-01 Epub Date: 2024-12-05 DOI: 10.1097/CCO.0000000000001107

Robert Pirker, Caicun Zhou

引用次数: 0

Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer. 免疫检查点抑制剂在驱动基因突变阳性非小细胞肺癌中的应用。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-01-01 Epub Date: 2024-11-02 DOI: 10.1097/CCO.0000000000001110

Rudolf M Huber, Diego Kauffmann-Guerrero

引用次数: 0

Novel immunotherapeutic approaches in lung cancer: driving beyond programmed death-1/programmed death ligand-1 and cytotoxic T-lymphocyte-associated Protein-4. 肺癌的新型免疫治疗方法：超越程序性死亡-1/程序性死亡配体-1 和细胞毒性 T 淋巴细胞相关蛋白-4。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-01-01 Epub Date: 2024-10-28 DOI: 10.1097/CCO.0000000000001106

Blerina Resuli, Diego Kauffmann-Guerrero

引用次数: 0

Thymic malignancies: role of immunotherapy and novel approaches. 胸腺恶性肿瘤：免疫疗法的作用和新方法。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-01-01 Epub Date: 2024-09-23 DOI: 10.1097/CCO.0000000000001101

Barbara Kiesewetter, Philipp Melhorn, Thorsten Fuereder

{"title":"Thymic malignancies: role of immunotherapy and novel approaches.","authors":"Barbara Kiesewetter, Philipp Melhorn, Thorsten Fuereder","doi":"10.1097/CCO.0000000000001101","DOIUrl":"10.1097/CCO.0000000000001101","url":null,"abstract":"Purpose of review: Thymic epithelial tumors (TETs) are a diverse group of malignancies that include thymomas (T), thymic carcinomas (TC), and thymic neuroendocrine tumors. Given the rarity of this disease, evidence defining the optimal treatment approach in the advanced/metastatic setting is limited. This article reviews the latest advances in systemic therapy for TETs, with a special focus on immunotherapy and targeted therapy strategies.Recent findings: Multiple recent efforts have been made to integrate novel immunotherapies and targeted therapy approaches into the current treatment algorithm for T and TC. In addition to trials of checkpoint inhibitor monotherapy, combinatorial approaches with novel immunotherapies or targeted therapies are being explored. Molecular profiling may help identify druggable targets, further optimizing outcomes in this population.Summary: Immune checkpoint inhibitor therapy has shown promising activity in TETs patients. However, toxicity in an unselected cohort, particularly in T patients, can be substantial, and therefore it is not recommended outside of clinical trials. Until additional research validates biomarkers to safely select patients for immunotherapy, targeted therapies remain a reasonable second-line option. Contemporary next-generation sequencing panels may be applied to identify druggable targets in the absence of standard treatment.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"84-94"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in immunotherapy for small cell lung cancer. 小细胞肺癌免疫疗法的最新进展。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-01-01 Epub Date: 2024-11-02 DOI: 10.1097/CCO.0000000000001105

Ziyuan Ren, Shijie Shang, Dawei Chen

{"title":"Recent advances in immunotherapy for small cell lung cancer.","authors":"Ziyuan Ren, Shijie Shang, Dawei Chen","doi":"10.1097/CCO.0000000000001105","DOIUrl":"10.1097/CCO.0000000000001105","url":null,"abstract":"Purpose of review: This review aims to provide an overview of recent advances in immunotherapy for small cell lung cancer (SCLC), with a focus on the current status of immune checkpoint inhibitors (ICIs), novel combination strategies, and key biomarkers.Recent findings: The integration of ICIs into standard chemotherapy has established them as the first-line treatment for extensive-stage SCLC (ES-SCLC). The ADRIATIC trial further demonstrated the efficacy of ICI maintenance therapy in limited-stage SCLC. Additionally, combining radiotherapy with ICIs has shown promising synergistic effects, including the abscopal and radscopal effects. Ongoing investigations into the combination of ICIs with targeted therapies, such as antiangiogenic agents and DNA damage response inhibitors, have yielded encouraging preliminary results. Notably, the novel therapeutic agent tarlatamab, the first bispecific DLL3-directed CD3 T-cell engager, has recently received FDA approval for second-line treatment of ES-SCLC. Advances in omics technologies have shed light on the intra-tumor and inter-tumor heterogeneity of SCLC, leading to the identification of new molecular subtypes and biomarkers, thereby paving the way for precision medicine.Summary: Despite the improved outcomes associated with immunotherapy in SCLC, the overall clinical benefit remains modest. Further preclinical and clinical studies are essential to identify optimal treatment regimens and enhance therapeutic efficacy.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"17-26"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0